TY  - JOUR
AU  - Renovanz, Mirjam
AU  - Kurz, Sylvia C
AU  - Rieger, Johannes
AU  - Walter, Bianca
AU  - Becker, Hannes
AU  - Hille, Hanni
AU  - Bombach, Paula
AU  - Rieger, David
AU  - Grosse, Lucia
AU  - Häusser, Lara
AU  - Skardelly, Marco
AU  - Merk, Daniel J
AU  - Paulsen, Frank
AU  - Hoffmann, Elgin
AU  - Gani, Cihan
AU  - Neumann, Manuela
AU  - Beschorner, Rudi
AU  - Rieß, Olaf
AU  - Roggia, Cristiana
AU  - Schroeder, Christopher
AU  - Ossowski, Stephan
AU  - Armeanu-Ebinger, Sorin
AU  - Gschwind, Axel
AU  - Biskup, Saskia
AU  - Schulze, Martin
AU  - Fend, Falko
AU  - Singer, Stephan
AU  - Zender, Lars
AU  - Lengerke, Claudia
AU  - Brucker, Sara Yvonne
AU  - Engler, Tobias
AU  - Forschner, Andrea
AU  - Stenzl, Arnulf
AU  - Kohlbacher, Oliver
AU  - Nahnsen, Sven
AU  - Gabernet, Gisela
AU  - Fillinger, Sven
AU  - Bender, Benjamin
AU  - Ernemann, Ulrike
AU  - Öner, Öznur
AU  - Beha, Janina
AU  - Malek, Holly Sundberg
AU  - Möller, Yvonne
AU  - Ruhm, Kristina
AU  - Tatagiba, Marcos
AU  - Schittenhelm, Jens
AU  - Bitzer, Michael
AU  - Malek, Nisar
AU  - Zips, Daniel
AU  - Tabatabai, Ghazaleh
TI  - Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system.
JO  - Neuro-oncology advances
VL  - 5
IS  - 1
SN  - 2632-2498
CY  - Oxford
PB  - Oxford University Press
M1  - DKFZ-2023-00528
SP  - 1-14
PY  - 2023
AB  - The clinical utility of molecular profiling and targeted therapies for neuro-oncology patients outside of clinical trials is not established. We aimed at investigating feasibility and clinical utility of molecular profiling and targeted therapy in adult patients with advanced tumors in the nervous system within a prospective observational study.molecular tumor board (MTB)@ZPM (NCT03503149) is a prospective observational precision medicine study for patients with advanced tumors. After inclusion of patients, we performed comprehensive molecular profiling, formulated ranked biomarker-guided therapy recommendations based on consensus by the MTB, and collected prospective clinical outcome data.Here, we present initial data of 661 adult patients with tumors of the nervous system enrolled by December 31, 2021. Of these, 408 patients were presented at the MTB. Molecular-instructed therapy recommendations could be made in 380/408 (93.1
KW  - MTB@ZPM-001 (NCT03503149) (Other)
KW  - Molecular tumor board (Other)
KW  - precision medicine (Other)
KW  - real-world data (Other)
KW  - targeted therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36915613
C2  - pmc:PMC10007909
DO  - DOI:10.1093/noajnl/vdad012
UR  - https://inrepo02.dkfz.de/record/274242
ER  -